MAJOR CONTRACTS CAPEXHealthcare

Neuland Laboratories Ltd. announces a new order win

Neuland Laboratories Ltd.NEULANDLAB

TL;DR

The total capitalized cost of expansion and historical asset turnover ratios specifically for Unit 1 and Unit 3 are not separately disclosed in the company's reported financial disclosures or structured KPI dataset. To evaluate the broader asset base expansion and company-wide asset turnover performance across recent fiscal years: Asset Turnover (Consolidated): Recorded at 0.95x in FY24, 0.77x in FY25, and 0.85x in FY26.

What is the total capitalized cost of the expansion at Unit 1 and Unit 3, and how does this incremental asset base compare to the company's historical asset turnover ratios for these specific manufacturing sites?

The total capitalized cost of expansion and historical asset turnover ratios specifically for Unit 1 and Unit 3 are not separately disclosed in the company's reported financial disclosures or structured KPI dataset.

To evaluate the broader asset base expansion and company-wide asset turnover performance across recent fiscal years:

  • Asset Turnover (Consolidated): Recorded at 0.95x in FY24, 0.77x in FY25, and 0.85x in FY26 [1]. Standalone asset turnover tracks similarly at 0.95x, 0.77x, and 0.86x over the same periods [2].
  • Fixed Assets (Consolidated): Expanded from Rs 850.53 Crores in FY24 to Rs 999.46 Crores in FY25 and Rs 1,386.40 Crores in FY26 [3].
  • Capital Work in Progress (CWIP): Stood at Rs 45.89 Crores in FY24, Rs 44.55 Crores in FY25, and surged to Rs 209.50 Crores in FY26 (a 370.3% YoY increase) [4], reflecting ongoing facility expansion and capital deployment.

Based on the project announcements leading up to this commercialization, what is the specific breakdown of the incremental capacity (in KL or tonnage) added at Unit 1 versus Unit 3, and does this expansion target specific product categories like Peptides or complex APIs?

I couldn't find relevant information for this query. Please try rephrasing or asking about a specific metric.

How does the capital intensity of this brownfield expansion at Unit 1 and Unit 3 compare to the company's previous capacity additions, and what is the management's stated guidance on the timeline for achieving optimal capacity utilization at these new facilities?

Consolidated capital expenditure increased across recent fiscal years, rising from Rs 141.46 Crores in FY24 to Rs 206.46 Crores in FY25, and reaching Rs 390.17 Crores in FY26 [5]. Capital Work in Progress (CWIP) stood at Rs 45.89 Crores in FY24, Rs 44.55 Crores in FY25, and rose to Rs 209.50 Crores in FY26 [4], pointing to an acceleration in ongoing project execution and asset buildout.

Unit-level details regarding the brownfield expansion at Unit 1 and Unit 3, capital intensity comparisons against previous capacity additions, and management's stated guidance on the timeline for achieving optimal capacity utilization at these new facilities are not reported.

Sources

  1. [1]TTM Asset Turnover
  2. [2]TTM Asset Turnover
  3. [3]Fixed Assets
  4. [4]Capital Work in Progress
  5. [5]TTM Capex

Keep digging

What is the total capitalized cost of the expansion at Unit 1 and Unit 3, and how does this incremental asset base compare to the company's historical asset turnover ratios for these specific manufacturing sites?

Ask Copilot
Logo

Unlock financial AI for your firm

Log in